These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16118328)

  • 1. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?
    Rodrigues AD
    Drug Metab Dispos; 2005 Nov; 33(11):1567-75. PubMed ID: 16118328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
    Agúndez JA; García-Martín E; Martínez C
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):607-20. PubMed ID: 19422321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
    Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
    J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
    García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
    Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
    Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
    Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
    Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
    Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
    Rodrigues AD; Yang Z; Chen C; Pray D; Kim S; Sinz M
    Clin Pharmacol Ther; 2006 Sep; 80(3):298-301; author reply 301-02. PubMed ID: 16952496
    [No Abstract]   [Full Text] [Related]  

  • 10. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
    Choi CI; Kim MJ; Jang CG; Park YS; Bae JW; Lee SY
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):476-80. PubMed ID: 21726410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
    Kirchheiner J; Störmer E; Meisel C; Steinbach N; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Aug; 13(8):473-80. PubMed ID: 12893985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
    Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.
    Bae JW; Choi CI; Jang CG; Lee SY
    Br J Clin Pharmacol; 2011 Apr; 71(4):550-5. PubMed ID: 21395648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].
    Martínez C; Blanco G; García-Martín E; Agúndez JA
    Farm Hosp; 2006; 30(4):240-8. PubMed ID: 17022718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
    López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
    Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
    Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.